Bosnalijek

Bosnalijek is a pharmaceutical company based in Sarajevo, Bosnia and Herzegovina. Established in 1951, it stands as the largest pharmaceutical enterprise within Bosnia and Herzegovina, with operations spanning more than 20 countries and generating an annual income close to €80.91 million as of 2018.

History

Bosnalijek was founded in 1951 in Sarajevo, which was part of FPR Yugoslavia at the time, and has developed into a prominent regional pharmaceutical entity. In 2005, the International Finance Corporation provided a €7.5 million loan to facilitate the construction of a production and distribution facility worth €18.5 million, significantly boosting its manufacturing capacity.

The company became fully privatized in October 2016 when the Federation of Bosnia and Herzegovina government divested its remaining shares. By 2019, international markets accounted for 76% of Bosnalijek’s revenue, demonstrating its effective export-focused strategy and expansive global presence.

Major investors include Haden S.A., holding 25.95%, and KBC Euro Credit Capital with 23.68%. Employing approximately 720 people in 2019, Bosnalijek’s product range comprises solid oral dosage forms, ampoule medications, galenic formulations, as well as non-pharmaceutical chemical items, strengthening its position within the pharmaceutical sector.

Under the guidance of CEO Adnan Hadžić, the company emphasizes market share growth and sustainable development through innovation and global market penetration.